IGF2BP1: A Crucial Driver of Cancer Progression and a Therapeutic Target
The RNA-binding protein IGF2BP1 has emerged as a key regulator of cancer hallmarks, influencing tumor proliferation, metastasis, immune evasion, and resistance to cell death. As an m6A reader, IGF2BP1 binds to methylated mRNA, stabilizing oncogenic transcripts and promoting cancer progression. Its role in regulating gene expression at the post-transcriptional level has positioned IGF2BP1 as a potential biomarker for cancer prognosis and a target for novel anti-tumor therapies. Increased expression of IGF2BP1 has been observed in various cancers, including lung, liver, breast, and colorectal cancer, correlating with poor prognosis and therapeutic resistance. By interacting with m6A-modified mRNAs, IGF2BP1 enhances the stability and translation of cancer-driving genes, fueling tumor growth, invasion, and metabolic reprogramming. Its ability to promote immune evasion by stabilizing PD-L1 mRNA underscores its role in suppressing anti-tumor immunity. By influencing ferroptosis resistance, IGF2BP1 contributes to cancer cell survival under oxidative stress.…





